

target organ for thyroid hormone. Overt hypothyroidism can cause symptoms compatible with depression. However, its relationship with subclinical hypothyroidism (SCH) is not well established.

Objectives: To review the literature regarding the effect of levothyroxine therapy among patients with SCH and coexistent depression.

Methods: We conducted a MEDLINE search using depression, subclinical hypothyroidism and levothyroxine as keywords, selecting studies written in English.

Results: SCH is defined as an elevated thyroid stimulating hormone with normal peripheral hormone levels. The association between SCH and depression is controversial. Some studies indicate that SCH had the same propensity with overt hypothyroidism, while others report that major affective symptoms are not associated with SCH, but are likely due to independent psychiatric diagnoses, which are common in the general population and occur with similar frequency in patients with SCH. Individuals with SCH are recommended to initiate levothyroxine replacement therapy only when their TSH level is above 10 mIU/L or if symptoms are present. There is a lack of evidence supporting the use of levothyroxine therapy to improve mental health outcomes and the majority of meta-analysis do not show relief of affective symptoms after levothyroxine therapy, among individuals with SCH.

Conclusions: Routine screening for depressive symptoms among individuals with SCH is important to prevent morbidity. Nevertheless, there is no evidence enduring levothyroxine supplementation in these cases. Further studies, with larger sample sizes and longer follow-up periods are needed to enlighten the potential benefit of this therapy.

Disclosure: No significant relationships.

Keywords: subclinical hypothyroidism; levothyroxine; Depression

EPV0629

Pharmacological Treatment Strategies for Postpartum Depression

O. Vasiliu

Dr. Carol Davila University Emergency Central Military Hospital, Psychiatry, Bucharest, Romania
doi: 10.1192/j.eurpsy.2022.1438

Introduction: Postpartum depression (PPD) is an important cause of discomfort and dysfunction that impair the quality of life and the daily functionality not only of the patient but also of her child and her family, in its entirety. New treatment options have been made available for this pathology, but their use is restricted by methodological aspects, like the difficulty of administration, lack of enough data regarding their long-term efficacy, and costs.

Objectives: To conduct a literature review in order to find the most evidence-based pharmacological interventions for PPD.

Methods: A literature review was performed through the main electronic databases (PubMed, CINAHL, SCOPUS, EMBASE) using the search paradigm “postpartum depression” AND “treatment” OR “pharmacological agents”. All papers published between January 2000 and August 2021 were included.

Results: Among the most evidence-based agents for PPD treatment are serotonin selective reuptake inhibitors (SSRIs). As individual agents, sertraline seems to be the most supported antidepressant by evidence from clinical trials, followed by escitalopram/citalopram,

and fluoxetine. Other antidepressants supported by clinical data were venlafaxine, desvenlafaxine, nortriptyline, and bupropion. A 6-12 months maintenance treatment is considered optimal after remission, in women with a low risk of recurrence. Brexanolone, zuranolone, and ganaxolone are members of a new class of drugs studied for postpartum depression, but currently, only the first agent is FDA-approved for this indication.

Conclusions: SSRIs are the most supported by evidence treatments for PPD, and brexanolone is a drug with a new mechanism, dedicated to this pathology that provides new hope for recovery.

Disclosure: No significant relationships.

Keywords: Antidepressants; postpartum depression; Brexanolone

EPV0630

Multidisciplinary treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding.

S.S. Sánchez Rus^{1*}, S. Suárez-Gómez² and D. Sanchez R.³

¹University Hospital Jaén, Psychiatry, Jaén, Spain; ²Hospital José Joaquim Fernandes, Psychiatry, Beja, Portugal and ³Hospital Universitario Insular Materno-Infantil, Puerperium Unit, Las Palmas GC, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.1439

Introduction: Postpartum depression is a common psychiatric complication after pregnancy, so it is necessary to know the depressive symptoms to be able to carry out early prevention and treatment interventions. It is a health problem with a prevalence that ranges between 10–15% according to the world literature. Behavioral and psychosocial factors favoring postpartum depression are recognized.

Objectives: -To emphasize multidisciplinary treatment in the combined attention to the mother-baby. -To demonstrate decreased risk for baby if early use of antidepressants. -To evaluate of the impact of desvenlafaxine during breastfeeding.

Methods: Descriptive-study. Clinical Case. Evolution of postpartum depression. Follow-up of a patient based on coordination with the midwife attending a successful breastfeeding while treatment with desvenlafaxine. Use of Edinburgh Postnatal Depression Scale.

Results: -Use of Desvenlafaxine 50-100mg being compatible with breastfeeding, in addition to depressive illness improvement (*Obstetrics and psychiatry guidelines and safety considerations for lactation and antidepressants).

Conclusions: -Postpartum-depression could be the first episode of depression in a healthy woman. Sometimes there are unnoticed symptoms during pregnancy. -Health-care for puerperal women should be focused on both, biomedical and psychosocial issues, with a coordinated multidisciplinary team. -Due to important early treatment during the puerperium, it is recommended a close medical control of the mother's psychological state after the birth. -If depression appears, a psychiatric follow-up is kept even after the episode remission. Besides, the role of the midwife is essential during lactation. -Some antidepressants like desvenlafaxine have demonstrated benefits over the risk of the baby's complications without treatment.

Disclosure: No significant relationships.

Keywords: postpartum depression; desvenlafaxine; multidisciplinary treatment; breastfeeding